Myths, Truths, and Clinical Relevance of Comedogenicity Product Labeling

• Autores: Melody Maarouf, Chantal Saberian, Vivian Y. Shi
• Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 154, Nº. 10, 2018, págs. 1131-1132
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • he concept of acne cosmetica was first introduced in 1972 to describe low-grade persistent acneiform eruptions in women who use cosmetics daily.1 Although histologically similar to acne vulgaris, which forms from abnormal differentiation and proliferation of keratinocytes in the follicular duct, acne cosmetica comedones are smaller and closed and show less sebaceous gland involution.1 Although sebum composition, follicular hyperkeratosis, androgens, and cytokines are implicated in the pathogenesis of acne vulgaris, acne cosmetica results from the prolonged use of cosmetic compounds that block follicular ducts. In 1972, 28% of adolescents and 4% of women (≥31 years of age) were affected.1 We believe that the prevalence of acne cosmetica is increasing with cosmeceutical industry growth. Thus, comedogenicity is an important consumer consideration.